Tempus AI Inc

Tempus AI Inc(TEM)股票分析

$67.760

+1.023 (+1.51%)收盘时

Loading chart…
最高
68.930
开盘
66.875
成交量加权均价
67.56
成交量
3.38M
市值
—
最低
66.000
成交额
228.53M
企业价值/息税折旧摊销前利润(TTM)
-46.09

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

AI 分析 of Tempus AI Inc (TEM)

持有

Tempus AI Inc is currently not a good buy due to its recent price decline and negative earnings, despite some positive revenue growth. The current price is $64.72, which is significantly below the analyst price targets ranging from $66 to $95. However, the RSI is at 30.406, indicating that the stock is oversold, which could present a buying opportunity if the fundamentals improve. The main risk is the company's high debt-to-equity ratio of 305.82%, which raises concerns about financial stability.

估值指标

Tempus AI Inc(TEM)当前预期市盈率为 0.00,5 年平均预期市盈率为 -97.78。

预期市盈率

高估
5 年均值 P/E
-97.78
当前P/E
0.00
高估
-43.08
低估
-152.47

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
36.14
当前EV/EBITDA
-46.09
高估
1278.50
低估
-1206.23

预期市销率

合理
5 年均值 P/S
7.42
当前P/S
6.12
高估
9.56
低估
5.28

持有 TEM 的大户

A

ARK Investment Management LLC

+ 持有TEM

+20.80%

3个月收益率

A

Allen Holding Inc.

+ 持有TEM

+16.65%

3个月收益率

S

Sanlam Investments Uk Limited

+ 持有TEM

+6.84%

3个月收益率

C

Capital Impact Advisors, LLC

+ 持有TEM

-0.06%

3个月收益率

K

KKR & Co. Inc.

+ 持有TEMHSIC

-1.55%

3个月收益率

事件时间线

2026-10-19 (ET)

09:00:00

Tempus AI Announces Results of NSCLC Study

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

09:00:00

Tempus Expands Collaboration with Merck for Personalized Cancer Therapy

2026-09-28 (ET)

08:30:00

Tempus AI Receives FDA Clearance for ECG-MR Product

资讯

TEM 常见问题 —— 由 Alphio AI 解答

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. It operates in the Healthcare sector.

Tempus AI Inc is currently not a good buy due to its recent price decline and negative earnings, despite some positive revenue growth. The current price is $64.72, which is significantly below the analyst price targets ranging from $66 to $95. However, the RSI is at 30.406, indicating that the stock is oversold, which could present a buying opportunity if the fundamentals improve. The main risk is the company's high debt-to-equity ratio of 305.82%, which raises concerns about financial stability.

$TEM (+3.4% pre) Tempus AI study shows AI pre-screening potential for lung cancer testing

展开

There is still some time for some names ahead of the $MRNA presentation on Saturday... People will FOMO into these personalized treatment names — not if, but when. $TEM is one of them.

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易